Jazz Pharmaceuticals(US:JAZZ) ZACKS·2025-08-05 22:16Company Performance - Jazz Pharmaceuticals reported a quarterly loss of $8.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $6.12, and a significant decline from earnings of $5.3 per share a year ago, indicating an earnings surprise of -34.80% [1] - The company posted revenues of $1.05 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.26%, but showing a slight increase from year-ago revenues of $1.02 billion [2] - Over the last four quarters, Jazz has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Jazz shares have declined approximately 5.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $5.08 on revenues of $1.11 billion, and for the current fiscal year, it is $4.93 on revenues of $4.24 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Jazz belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]